Development of a Novel, Fully-Automated Genotyping System: Principle and Applications
Genetic testing prior to treatment, pharmacogenetic analysis, is key to realizing personalized medicine which is a topic that has attracted much attention recently. Through the optimization of therapy selection and dosage, a reduction in side effects is expected. Genetic testing has been conducted a...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2012-12-01
|
| Series: | Sensors |
| Subjects: | |
| Online Access: | http://www.mdpi.com/1424-8220/12/12/16614 |
| _version_ | 1811213310498963456 |
|---|---|
| author | Shun-ichi Suzuki Mariko Komori Mitsuharu Hirai Norio Ureshino Shinya Kimura |
| author_facet | Shun-ichi Suzuki Mariko Komori Mitsuharu Hirai Norio Ureshino Shinya Kimura |
| author_sort | Shun-ichi Suzuki |
| collection | DOAJ |
| description | Genetic testing prior to treatment, pharmacogenetic analysis, is key to realizing personalized medicine which is a topic that has attracted much attention recently. Through the optimization of therapy selection and dosage, a reduction in side effects is expected. Genetic testing has been conducted as a type of pharmacogenetic analysis in recent years, but it faces challenges in terms of cost effectiveness and its complicated procedures. Here we report on the development of a novel platform for genetic testing, the i-densyTM, with the use of quenching probe system (QP-system) as principle of mutant detection. The i-densyTM automatically performs pre-treatment, PCR and detection to provide the test result from whole blood and extracted DNA within approximately 90 and 60 min, respectively. Integration of all steps into a single platform greatly reduces test time and complicated procedures. An even higher-precision genetic analysis has been achieved through the development of novel and highly-specific detection methods. The applications of items measured using the i-densyTM are diverse, from single nucleotide polymorphism (SNP), such as CYP2C19 and UGT1A1, to somatic mutations associated with cancer, such as EGFR, KRAS and JAK2. The i-densyTM is a useful tool for optimization of anticancer drug therapy and can contribute to personalized medicine. |
| first_indexed | 2024-04-12T05:44:39Z |
| format | Article |
| id | doaj.art-d4813bf5aa8d457a9b5e5bb707d8242d |
| institution | Directory Open Access Journal |
| issn | 1424-8220 |
| language | English |
| last_indexed | 2024-04-12T05:44:39Z |
| publishDate | 2012-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Sensors |
| spelling | doaj.art-d4813bf5aa8d457a9b5e5bb707d8242d2022-12-22T03:45:30ZengMDPI AGSensors1424-82202012-12-011212166141662710.3390/s121216614Development of a Novel, Fully-Automated Genotyping System: Principle and ApplicationsShun-ichi SuzukiMariko KomoriMitsuharu HiraiNorio UreshinoShinya KimuraGenetic testing prior to treatment, pharmacogenetic analysis, is key to realizing personalized medicine which is a topic that has attracted much attention recently. Through the optimization of therapy selection and dosage, a reduction in side effects is expected. Genetic testing has been conducted as a type of pharmacogenetic analysis in recent years, but it faces challenges in terms of cost effectiveness and its complicated procedures. Here we report on the development of a novel platform for genetic testing, the i-densyTM, with the use of quenching probe system (QP-system) as principle of mutant detection. The i-densyTM automatically performs pre-treatment, PCR and detection to provide the test result from whole blood and extracted DNA within approximately 90 and 60 min, respectively. Integration of all steps into a single platform greatly reduces test time and complicated procedures. An even higher-precision genetic analysis has been achieved through the development of novel and highly-specific detection methods. The applications of items measured using the i-densyTM are diverse, from single nucleotide polymorphism (SNP), such as CYP2C19 and UGT1A1, to somatic mutations associated with cancer, such as EGFR, KRAS and JAK2. The i-densyTM is a useful tool for optimization of anticancer drug therapy and can contribute to personalized medicine.http://www.mdpi.com/1424-8220/12/12/16614automated genotyping systempharmacogenetic analysissingle nucleotide polymorphismi-densyTMQprobemutation biased PCRpersonalized medicine |
| spellingShingle | Shun-ichi Suzuki Mariko Komori Mitsuharu Hirai Norio Ureshino Shinya Kimura Development of a Novel, Fully-Automated Genotyping System: Principle and Applications Sensors automated genotyping system pharmacogenetic analysis single nucleotide polymorphism i-densyTM Qprobe mutation biased PCR personalized medicine |
| title | Development of a Novel, Fully-Automated Genotyping System: Principle and Applications |
| title_full | Development of a Novel, Fully-Automated Genotyping System: Principle and Applications |
| title_fullStr | Development of a Novel, Fully-Automated Genotyping System: Principle and Applications |
| title_full_unstemmed | Development of a Novel, Fully-Automated Genotyping System: Principle and Applications |
| title_short | Development of a Novel, Fully-Automated Genotyping System: Principle and Applications |
| title_sort | development of a novel fully automated genotyping system principle and applications |
| topic | automated genotyping system pharmacogenetic analysis single nucleotide polymorphism i-densyTM Qprobe mutation biased PCR personalized medicine |
| url | http://www.mdpi.com/1424-8220/12/12/16614 |
| work_keys_str_mv | AT shunichisuzuki developmentofanovelfullyautomatedgenotypingsystemprincipleandapplications AT marikokomori developmentofanovelfullyautomatedgenotypingsystemprincipleandapplications AT mitsuharuhirai developmentofanovelfullyautomatedgenotypingsystemprincipleandapplications AT norioureshino developmentofanovelfullyautomatedgenotypingsystemprincipleandapplications AT shinyakimura developmentofanovelfullyautomatedgenotypingsystemprincipleandapplications |